SCHEMBL12154149

SCHEMBL12154149

CCc1ccc(C(=O)Oc2ccc(C)c(C)c2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.52
▸ MAPT P10636 6/20 0.48
▸ LMNA P02545 2/20 0.48
▸ GAA P10253 1/20 0.48
▸ NPC1 O15118 4/20 0.48
▸ L3MBTL1 Q9Y468 3/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ RXRA P19793 1/20 0.46
▸ RXRB P28702 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ TP53 P04637 1/20 0.45
▸ POLB P06746 1/20 0.45
▸ RAB9A P51151 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12154216 0.89 MAPT (0.47) KMT2AMAPTLMNAL3MBTL1RXRA
SCHEMBL18418538 0.86 MRGPRX4 (0.47) KMT2AMAPTLMNAGAASMN1; SMN2
SCHEMBL13527667 0.85 KMT2A (0.65) KMT2AMAPTLMNAGAANPC1
SCHEMBL13527668 0.85 KMT2A (0.61) KMT2AMAPTLMNAGAANPC1
SCHEMBL12154244 0.85 KMT2A (0.59) KMT2AMAPTLMNATDP1RXRA
SCHEMBL13539007 0.84 KMT2A (0.69) KMT2AMAPTLMNAGAANPC1
SCHEMBL12154217 0.84 ALDH1A1 (0.57) KMT2AMAPTLMNASMN1; SMN2RXRA
SCHEMBL12154283 0.84 ALDH1A1 (0.57) KMT2AMAPTLMNASMN1; SMN2RXRA
SCHEMBL26832415 0.84 ALDH1A1 (0.57) KMT2AMAPTLMNASMN1; SMN2RXRA
SCHEMBL12199916 0.84 ALDH1A1 (0.57) KMT2AMAPTLMNASMN1; SMN2RXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120274888-A1 OPTICALLY ANISOTROPIC SUBSTANCE JNC PETROCHEMICAL CORPORATION (JP) 2012-11-01 — — US disclosed
US-8048496-B2 Polymerizable liquid crystal compound, liquid crystal composition and polymer JNC CORPORATION (JP) 2011-11-01 — — US disclosed
US-20100297367-A1 OPTICALLY ANISOTROPIC SUBSTANCE CHISSO CORPORATION (JP) 2010-11-25 — — US disclosed
US-20100096591-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND POLYMER CHISSO CORPORATION 2010-04-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100096591-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND POLYMER PKN1, ZYX, OXER1 KMT2A 1370/4885MAPT 2557/4885LMNA 607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback